Analysis reveals treatment decisions are influenced by performance status and tumor traits, not staging in Poland.
In Poland, cCRT and sCRT are equally used. Treatment decisions are primarily driven by PS and tumor characteristics rather than UICC-TNM staging.
No takes yet. Share an insight, caveat, or question.
Kuncman et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: